


## Procare Health and UCLA University undertake a World-Pioneering Research to Create a Cervical Cancer Chip

This laboratory project will help to understand first-hand the behavior of the cervical cells in order to understand the mechanisms of HPV and develop drugs that represents advances on its treatment.

The research carried out by Procare Health already exceeds 20% of its annual turnover, which has enabled it to present innovative solutions to problems related to women's health such as Papilocare.

Procare Health, which is specialized in women's health, has closed a collaboration agreement with the California Nanosystem Institute at the University of UCLA for the development of a cervix on chip. In particular, this process will aim to advance their studies on HPV to combat against its spread. This agreement represents the union of the latest technology applied by this university center, which in recent years has been committed to the development of organs in chips, with the medical and health knowledge that Procare Health has acquired in HPV matters. For that, the laboratory has made one of its top experts available to the Institute, Dr. Danial Khorsandi, who will be responsible for the research in California.



*Illustration 1. Chip's model developed by UCLA University and Procare Health*

In this case, a chip will be developed to analyze the mechanism of infection of HPV, the cellular integration of the virus and the role of endocervical and exocervical epithelial cells. This will be developed with the aim of understanding the mechanism of therapeutic action of Papilocare and discovering new therapies. Furthermore, one of the main lines of future action will be precisely the research on this treatment, one of the main products developed by the Spanish laboratory. The high prevalence of the virus (it is estimated that 80% of people have suffered it at some time), is the main cause of cervical cancer in women.

---




Illustration 2. CNSI at UCLA University

---

*"This is a research project that will offer a greater understanding of how the cervix works. Women's health is our main focus, and this collaboration agreement with UCLA lays the foundation for unprecedented health and technology development that aims to help improving the quality of life for a large percentage of the population."*

Yann Gaslain, CEO of Procure Health

---

## Research in women's health

Papilocare has become the first vaginal gel indicated for the prevention and treatment of HPV lesions. This product is formulated with natural ingredients (hyaluronic acid, Coriolus versicolor, Azadirachta indica (Neem), Betaglucan and Centella asiatica), with proven efficacy in the regression of intraepithelial lesions, and in particular, in the denial of HPV.

Its development is part of the R&D process of Procare Health that, since its creation in 2012, has carried out a strong research work within the area of women's health.

"Since we created the firm, the laboratory has invested 20% of its annual budget in R&D. It is a policy rooted in the company's DNA and through which it has been possible to identify and develop pioneering natural solutions for women's health, avoiding the usual hormonal therapies in these cases," concluded Yann Gaslain.

This commitment to the Research and Development has allowed the company to extend its presence in the market and to expand the distribution of its discoveries to other European countries, among which Portugal, Italy, Belgium, Luxembourg or the Balkans stand out.

---